Santen signs licence deal with Akorn for marketing of tafluprost in US

9th April 2014

Japan-based Santen Pharmaceutical (Santen) has signed a licensing agreement with Oak Pharmaceuticals, a subsidiary of Akorn, pertaining to the sales and marketing of tafluprost in the US.

Tafluprost, which is indicated for the treatment of glaucoma and ocular hypertension, is trademarked as Zioptan in the US and as Tapros in Japan.Oak recently acquired tafluprost business from Merck and has been granted the rights to sell and market the drug in the US by Santen pursuant to the agreement.


Read More at source article:

Leave a Reply

Your email address will not be published.

+ 1 = 8

« back to posts